Neisseria Meningitidis Clinical Trial
Official title:
An Observational Cross-sectional Study to Assess Oropharyngeal Carriage of N. Meningitidis in South Australian School Leavers
This is an observational cross sectional study to evaluate the impact of a 4CMenB vaccination program on oropharyngeal N. meningitidis carriage in vaccinated and unvaccinated school leavers.
This carriage study of a cohort of school leavers in South Australia (SA) will provide an opportunity to assess carriage rates in the young adult population (school leavers) following introduction of a 4CMenB vaccination program in senior school students from 2017-2018.This will allow a comparison of carriage prevalence in the two years (2018 and 2019) following implementation of the school program to assess impact on carriage at a population level and compare carriage prevalence in vaccinated versus non-vaccinated groups. Assessment of any association between risk factors and prevalence of nasopharyngeal carriage in school leavers will be made and compared between vaccinated and unvaccinated students. School leavers are defined as students who were enrolled in year 12 at school in the preceding year of recruitment and have been chosen as they are likely to have the highest carriage rates. A high proportion (approximately two thirds) of students will be immunised by the time of throat swab collection in years 2018 and 2019. Assessing carriage in both vaccinated and unvaccinated cohorts will further inform the effect of 4CMenB vaccine on carriage at a population level. This will help determine any herd immunity impact of 4CMenB vaccine and persistence of any effect. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01218451 -
NeisVac-C Single Prime Study in Infants
|
Phase 3 | |
| Completed |
NCT00323050 -
Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old Subjects
|
Phase 3 | |
| Completed |
NCT01090453 -
Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants
|
Phase 2 | |
| Completed |
NCT00454987 -
Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine
|
Phase 4 | |
| Completed |
NCT00891176 -
Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines
|
Phase 3 | |
| Completed |
NCT01839188 -
Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)
|
Phase 3 | |
| Completed |
NCT01553279 -
Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)
|
Phase 3 | |
| Completed |
NCT00263653 -
Safety, Reactogenicity & Immunogenicity Study to Evaluate a Booster Dose of GSK Biologicals' Hib-MenC Given With Priorix™ in Toddlers (13-14 m) Primed With 3 Doses of Hib and MenC-CRM197
|
Phase 3 | |
| Completed |
NCT00772070 -
Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine
|
Phase 2 | |
| Completed |
NCT00127855 -
Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine
|
Phase 2 | |
| Completed |
NCT00129116 -
3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age
|
Phase 2 | |
| Completed |
NCT00871338 -
Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants
|
Phase 2 | |
| Completed |
NCT00700635 -
Dose Comparison Study of Menactra® in US Children
|
Phase 2 | |
| Completed |
NCT00326118 -
Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.
|
Phase 3 | |
| Completed |
NCT01730391 -
Neisseria Meningitidis Burden of Disease Study
|
N/A | |
| Completed |
NCT00197795 -
Immunogenicity and Reactogenicity of a Meningococcal B Outer Membrane Vesicle Vaccine Given in a 0,6,12 Month Schedule to Health UK Adults
|
Phase 2 | |
| Completed |
NCT00289783 -
Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine
|
Phase 3 | |
| Completed |
NCT00444951 -
Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia
|
Phase 3 | |
| Completed |
NCT00258700 -
Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C Vaccine
|
Phase 3 | |
| Completed |
NCT01978093 -
Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age
|
Phase 3 |